aTyr Pharma Inc (NASDAQ:LIFE)’s share price was up 13.5% during trading on Wednesday . The stock traded as high as $6.95 and last traded at $6.83, approximately 400,863 shares were traded during mid-day trading. A decline of 68% from the average daily volume of 1,261,896 shares. The stock had previously closed at $6.02.
A number of brokerages have recently weighed in on LIFE. ValuEngine upgraded aTyr Pharma from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 7th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of aTyr Pharma in a research note on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $6.33.
The company has a debt-to-equity ratio of 0.19, a current ratio of 3.31 and a quick ratio of 3.31. The stock’s 50-day moving average price is $4.74 and its 200-day moving average price is $3.93. The company has a market cap of $23.42 million, a P/E ratio of -0.38 and a beta of 2.48.
aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Thursday, November 14th. The biotechnology company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.04). The company had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.06 million. As a group, analysts expect that aTyr Pharma Inc will post -6.72 EPS for the current fiscal year.
A hedge fund recently raised its stake in aTyr Pharma stock. Vanguard Group Inc. boosted its stake in shares of aTyr Pharma Inc (NASDAQ:LIFE) by 1.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,779,024 shares of the biotechnology company’s stock after acquiring an additional 33,702 shares during the period. Vanguard Group Inc. owned 54.32% of aTyr Pharma worth $652,000 at the end of the most recent reporting period. 47.76% of the stock is currently owned by hedge funds and other institutional investors.
aTyr Pharma Company Profile (NASDAQ:LIFE)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Recommended Story: What member countries make up the G-20?
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.